Multiple Sclerosis Drug Ocrelizumab Linked to Rare Lung Disease in New Study

Multiple sclerosis patients treated with ocrelizumab may face an increased risk of developing interstitial lung disease, according to new research published in JAMA Neurology. This finding raises important safety considerations for one of the most commonly prescribed disease-modifying therapies for MS.

Ocrelizumab is a monoclonal antibody that targets CD20-positive B cells and has proven highly effective at reducing MS relapses and disability progression. However, this immunosuppressive action may create vulnerabilities to certain complications.

Interstitial lung disease involves inflammation and progressive scarring of the lung tissue between air sacs, which can impair oxygen exchange and breathing function. The condition can range from mild to life-threatening, and early detection is crucial for management.

The research suggests this pulmonary complication emerges as a late occurrence in treatment, meaning patients who have been on ocrelizumab for extended periods may need particular attention. This timing pattern could indicate a cumulative effect of prolonged immune suppression or other mechanisms related to long-term B-cell depletion.

For clinicians, these findings underscore the importance of respiratory monitoring in MS patients receiving ocrelizumab, particularly those on long-term therapy. Patients should be educated about potential respiratory symptoms and the need for prompt medical evaluation if breathing difficulties develop. The research contributes to the growing understanding of long-term safety profiles for newer MS therapies, helping inform treatment decisions and monitoring protocols.